Publications by authors named "Alireza Manuchehri"
Purpose: To conduct a systematic literature review of the reliability, construct validity, and responsiveness of the SF-36 Health Survey (SF-36) in patients with ulcerative colitis (UC).
Methods: We performed a systematic search of electronic medical databases to identify published peer-reviewed studies which reported scores from the eight scales and/or two summary measures of the SF-36 collected from adult patients with UC. Study findings relevant to reliability, construct validity, and responsiveness were reviewed.
Objectives: To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC).
Methods: This retrospective cohort study identified the first pharmacy or medical claim for ADA or IFX (from January 1, 2007, to December 31, 2014) in patients with continuous enrollment for 6 months or more preindex and 12 months or more postindex, with one or more UC diagnosis claim 6 months pre- or postindex. TNFi discontinuation was defined as a therapy gap of 56 days or more for ADA and 112 days or more for IFX.
Article Synopsis
- The study investigates the impact of soy phytoestrogen supplementation on thyroid function in patients with subclinical hypothyroidism, amidst concerns about possible negative effects on thyroid health.
- Conducted as a randomized, double-blind, crossover trial with 60 participants, the study compared low-dose and high-dose phytoestrogen groups for 8 weeks each.
- Results indicated a significant increase in the risk of progressing to overt hypothyroidism with high-dose supplementation, along with beneficial effects on blood pressure, insulin resistance, and inflammation markers, though lipid profiles did not change.
Article Synopsis
- Dopamine agonists (DAs) can potentially reduce the size and secretion of prolactinomas by improving the tumor's blood vessel functionality, as visualized through DCE-MRI.
- A study with 23 participants (including patients with various types of prolactinomas and normal volunteers) showed that DAs significantly reduced prolactin levels and vascular parameters in most patients but not in normal subjects.
- The findings suggest that changes in tumor vascularity occur before any reduction in tumor size, and lack of these changes shortly after treatment may indicate resistance to DAs, possibly necessitating surgical intervention.
Background: B-type natriuretic peptides and N-terminal pro-B-type natriuretic peptides (NT-proBNP) have been suggested as being useful for the diagnosis of congestive heart failure. We have shown previously that changes in thyroid function are associated with changes in concentrations of other low molecular weight molecules. Therefore, the aim of this study was to assess whether similar changes occurred with NT-proBNP concentrations following treatment of thyroid dysfunction.
View Article and Find Full Text PDF